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Currently, children who receive prophylactic micafungin are
given daily dosing (1mg/kg/dose) or alternate day dosing
(3mg/kg/dose). We hypothesized that higher dose
micafungin (5 mg/kg) every 4 days will provide effective
anti-fungal prophylaxis, and improve patient compliance
(with essentially twice a week dosing regimen).
Objectives: To examinemicafungin PKwhen given at 5mg/kg
dose for anti-fungal prophylaxis to children undergoing HCT.
Methods: Nine children with various hematological, meta-
bolic and immune deﬁciency disorders undergoing HCT
received a single dose of micafungin (5 mg/kg) intravenously
over 1 hour. Dose selection was based on published PK data
in pediatric neutropenia patients (Seibel et al. 2005), our
alternate day micafungin PK study (Mehta et al. 2010), along
with Monte Carlo PK/PD simulation. Blood samples were
drawn around the micafungin infusion and at regular
intervals until 96 hours after. Plasma concentration data
were analyzed by noncompartmental (WinNonlin) and
population PK analysis (NONMEM).
Results:Micafungin at 5 mg/kg dose was well tolerated in all
subjects along with measurable plasma concentrations at 96
hours (Table 1). PK was best described by a 2-compartment
model in all subjects (Figure 1). The mean concentration at
96 hours was 0.11 mg/mL (Range: 0.03-0.26 mg/mL).
Concentrations at the end of the 96 hours remain above
the minimum inhibitory concentration (MIC) of susceptible
fungal pathogens (MIC >0.2 mg/ml) in 1 patient (11%) only.
However, target concentrations were achieved in 7/9 (78%)
patients at the end of 72 hours. When accounted for the
post-antifungal effect, all 9 (100%) patients were in the goal
range at the end of 72 hours.
Conclusion: Our data suggest that although micafungin at 5
mg/kg dosing generates suboptimal levels at the end of 4
days, observed levels at the end of 3 days were in the target
range, to cover susceptible fungal pathogens and provide an
attractive alternative for anti-fungal prophylaxis in children
undergoing HCT.
This study was supported by an unrestricted research grant
from Astellas Pharma US, Inc. The sponsor did not participate in
study design or interpretation of results.Table 1
Micafungin concentrations
Patient At 24 hrs
(mg/ml)
At 48 hrs
(mg/ml)
At 72 hrs
(mg/ml)
At 96 hrs
(mg/ml)
Mean 4.60 1.19 0.34 0.11
SD 1.07 0.36 0.15 0.08
Figure 1. PK proﬁle of micafungin337
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Background: Oral mucositis (OM) is the most debilitating
adverse effect of treatment from patient perspective during
Allogeneic Stem Cell Transplantation (ASCT).The intensity of
the conditioning regimen relates to both incidence & severity
of OM; however no previously published study has analyzed
this relationship. We sought to perform a meta-analysis and
systemic review on the incidence and outcomes of OM in
ASCT patients, and analyze this association.
Methods: A comprehensive search of several databases
(Ovid Medline In-Process & Other Non-Indexed Citations,
Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane CRCT, Ovid
Cochrane DSR and Scopus) from 1990-2014 for studies of OM
in ASCT patients was conducted by an experienced medical
librarian. To avoid ﬁle-drawer bias, professional society
meeting (ASH, EHA, ASBMT, EBMT, AAD) abstracts were
searched. Studies were includedwith strict eligibility - if they
reported the grade & incidence of OM with validated scales,
and provided details of conditioning regimen and Graft-
versus-host-disease (GVHD) prophylaxis (including doses
e.g. methotrexate). Grade of OM was analyzed based on the
WHO or NCI-CTCAE scales. For studies not utilizing these
scales, only overall incidence of OM was reported. Severe
mucositis was deﬁned as either Grade 2-4 or Grade 3-4
depending on the studies' deﬁnition of severity. Cohorts
were analyzed based on regimen intensity i.e. Reduced
Intensity Conditioning (RIC) [including Non-myeloablative]
and Myeloablative (MA).
Results: A total of 624 studies generated from the search
were reviewed. Of the 582 patients in 14 eligible MA regimen
studies, 75.4% experienced any OM, while in 245 patients
reviewed in the 6 eligible RIC regimen studies, 86.1%
experienced any OM (ﬁgures 1&2). A majority of studies
utilized the WHO or NCI-CTCAE scales. Severe OM occurred
in 73.3% of the WHO/NCI graded MA conditioning patients
and 67.8% of WHO/NCI graded RIC conditioned patients.
Other grading scales included in the studies were Oral
Mucositis Index, the Southwest Oncology Group (SWOG)
Criteria, and the Eastern Cooperative Oncology Group
(ECOG) scale. Due to the lack of randomized controlled trials
focusing on OM as the primary outcome variable and
heterogeneity of scales used to measure OM, a meta-analysis
could not be performed; however pooled analysis indicated
signiﬁcant differences in incidence of OM with respect to
different conditioning regimens (ﬁgures 1&2).
Conclusions: To our knowledge, this is the ﬁrst analysis on
OM in ASCT patients and we found that RIC regimens led to a
very high incidence of OM similar to that of MA regimens.
Clinical trials on treatment of OM are lacking emphasizing
the essential need for prospective studies in this arena. A
signiﬁcant variance in the criteria for grading OM
undermines the importance of establishing standard grading
system for OM measurement in future ASCT clinical trials
globally.
Figure 1. Incidence of Oral Mucosit is among patients receiving Myeloabiative (MA).
Figure 2. Incidence of Oral Mucosit is among patients receiving Reduced-Intensity Conditioning (RIC).
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Bacteremia during neutropenic episodes is a cause of
morbidity and mortality in patients undergoing
